Results 11 to 20 of about 15,580 (201)

52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic Hepatitis B [PDF]

, 2013
Background and Aims: The Roadmap concept is a therapeutic framework in chronic hepatitis B for the intensification of nucleoside analogue monotherapy based on early virologic response.
Aldo Trylesinski, AS Levey, AS Lok, BJ McMahon, CJ Chen, CL Lai, DJ Tenney, DJ Tenney, DW Cockcroft, EB Keeffe, Eduardo Fassio, Fernando Bessone, H Izzedine, H Mommeja-Marin, H Yang, Henry L. Y. Chan, HL Chan, Hugo Cheinquer, Javier R. Lama, JD Jia, Jorge Daruich, KL Andersson, Liver European Association For The Study Of The, MF Yuen, MF Yuen, Mário G. Pessôa, N Leung, P Marcellin, Piyawat Komolmit, Rashidkhan Pathan, RD Cooper, RG Gish, S Mauss, S Zeuzem, Stefan Zeuzem, Suzane K. Ono, Tawesak Tanwandee, Teerha Piratvisuth, Wattana Sukeepaisarnjaroen, YF Liaw, YF Liaw, Yuhong Dong   +41 more
core   +10 more sources

A Case of Severe Peripheral Polyneuropathy Occurring after Entecavir Treatment in a Hepatitis B Patient

The Korean Journal of Gastroenterology, 2016
Entecavir (BaracludeⓇ) is an oral antiviral drug used for the treatment of HBV. Entecavir is a reverse transcriptase inhibitor which prevents the HBV from multiplying.
Ji Hyun Song, Si Yeon Kim, Jae Kyoung Shin, So Dam Hong, Kyu Sung Rim, Ha Na Park, Joo Ho Lee, Yun Bin Lee, Seung Hun Oh, Seong Gyu Hwang   +9 more
doaj   +1 more source

Treatment with the Immunomodulator AIC649 in Combination with Entecavir Produces Antiviral Efficacy in the Woodchuck Model of Chronic Hepatitis B

Viruses, 2021
As current interventions for chronic hepatitis B (CHB) rarely induce cure, more effective drugs are needed. Short-term treatment of woodchucks with the novel immunomodulator AIC649, a parapoxvirus-based stimulator of toll-like receptor 9 dependent and ...
Kyle E. Korolowicz, Manasa Suresh, Bin Li, Xu Huang, Changsuek Yon, Xuebing Leng, Bhaskar V. Kallakury, Robin D. Tucker, Stephan Menne   +8 more
doaj   +1 more source

An expert consensus for the management of chronic hepatitis B in Asian Americans. [PDF]

, 2018
BACKGROUND: Hepatitis B virus (HBV) infection is common with major clinical consequences. In Asian Americans, the HBsAg carrier rate ranges from 2% to 16% which approximates the rates from their countries of origin.
Abbas, Abbas, Ahn, Beasley, Beasley, Bisceglie, Bogr, Brown, Buti, Centers for Disease Control, Chae, Chan, Chang, Chang, Chang, Chang, Chang, Chao, Chaung, Chen, Chen, Chen, Chen, Chi, Chien, Choe, Chu, Clemente, Della Corte, European Association for the Study of the Liver, Evans, Fang, Fattovich, Fontana, Fung, Gish, Hadziyannis, Halperin, Hann, Heathcote, Hongthanakorn, Hoofnagle, Hu, Huang, Hung, Hyun, Iino, Iloeje, Jeng, Keeffe, Kim, Komatsu, Konstantinou, Kowdley, Kuo, Kwong, Lai, Lai, Lai, Lai, Lampertico, Lau, Lau, Lee, Lee, Liang, Liaw, Liaw, Liaw, Liew, Lin, Lin, Lin, Liu, Liu, Liu, Lok, Lok, Lok, Loomba, MacLachlan, Manegold, Marcellin, Marcellin, Marcellin, Marcellin, Marcellin, Marcellin, Martin, Martin-Carbonero, Mast, McClune, McMahon, Mitchell, Monte, Murata, Mutimer, Nafa, Nguyen, Nguyen, Nikolopoulos, Pan, Pan, Pan, Pan, Pan, Pan, Pan, Pan, Pan, Pan, Papatheodoridis, Park, Park, Park, Patterson, Perrillo, Perrillo, Pollack, Prati, Qiu, Reijnders, Sarin, Seto, Seto, Sherman, Shim, Shiraki, Sinatra, Sinn, Soriano, Stevens, Takano, Takayama, Takkenberg, Terrault, Thibault, Thio, Tong, Tong, Tong, Tong, Tong, Tong, Tong, Tong, Tong, Tong, Tong, Tong, Tong, Tong, Tse, Wang, Wedemeyer, Wei, Wen, Wiseman, Wursthorn, Xie, Xu, Yi, Yi, Yu, Yu, Yuen, Yuen, Yuen, Yuen, Yuen, Zhang, Zhang, Zhang, Zou   +173 more
core   +2 more sources

Impact of HBcrAg levels on HBsAg seroconversion after HBV rebound: a case report

Journal of Pharmaceutical Health Care and Sciences, 2023
Background Nucleoside analogues (NAs) such as entecavir are required for at least 12 months when patients with resolved hepatitis B virus (HBV) infection develop HBV reactivation.
Maki Ohkubo, Kuniaki Fukuda, Shigeru Chiba, Masato Homma   +3 more
doaj   +1 more source

New Perspectives on Treatment of Hepatitis B Before and After Liver Transplantation [PDF]

, 2016
open5noThe hepatitis B virus (HBV) infects more than 260 million people globally, with increasing incidence, especially in developing countries.
Bortoluzzi, Ilaria, Burra, Patrizia, Ferrarese, Alberto, Russo, Francesco Paolo, Zanetto, Alberto   +4 more
core   +1 more source

“Black box warning” rash with entecavir - case report

BMC Gastroenterology, 2020
Background Hepatitis B infection is a significant worldwide health issue, predispose to the development of liver cirrhosis and hepatocellular carcinoma.
Xiong Khee Cheong, Zhiqin Wong, Norazirah Md Nor, Bang Rom Lee   +3 more
doaj   +1 more source

Reactivation of hepatitis B virus with immune-escape mutations after ocrelizumab treatment for multiple sclerosis [PDF]

, 2019
Ocrelizumab is an anti-CD20 monoclonal antibody for the treatment of multiple sclerosis (MS) that is closely related to rituximab. We describe a case of hepatitis B virus (HBV) reactivation in an MS patient with resolved HBV infection receiving ...
Altieri, Marta, Annecca, Rosanna, Aragri, Marianna, Ciardi, Maria R, Iannetta, Marco, Mastroianni, Claudio M, Pontecorvo, Simona, Russo, Gianluca, Salpini, Romina, Svicher, Valentina, Vullo, Vincenzo, Zingaropoli, Maria A   +11 more
core   +1 more source

Drug-related mutational patterns in hepatitis B virus (HBV) reverse transcriptase proteins from Iranian treatment-Naïve chronic HBV patients [PDF]

, 2013
Background: Immunomodulators and Nucleotide analogues have been used globally for the dealing of chronic hepatitis B virus (HBV) infection. However, the development of drug resistance is a major limitation to their long-term effectiveness.
Abedi, F., Alavian, S.M., Ataei, B., Azad, T.M., Daram, M., Fazeli, Z., Ghamari, S., Goodarzi, Z., Jazayeri, S.M., Judaki, M.A., Kalantari, E., Karimzadeh, H., Keyvani, H., Khedive, A., Mahabadi, M., Mahmoodi, M., Malekzadeh, R., Mansour-Ghanaei, F., Montazeri, G., Moradi, A., Nejatizadeh, A., Norouzi, M., Pourhosseingholi, M.A., Rafatpanah, H., Ramezani, F., Saberfar, E., Saberfiroozi, M., Samimirad, K., Sanei-Moghaddam, I., Sarizadeh, G., Sayad, B., Somi, M.H., Yaran, M., Ziee, M.   +33 more
core   +1 more source

Role of antiviral therapy in the natural history of hepatitis B virus-related chronic liver disease [PDF]

, 2015
Hepatitis B virus (HBV) infection is a dynamic state of interactions among HBV, hepatocytes, and the host immune system. Natural history studies of chronic hepatitis B (CHB) infection have shown an association between active viral replication and adverse
Farinati, Fabio, Gottardo, G, Rodr\uedguez Castro, K, Russo, FRANCESCO PAOLO, Scribano, L, Vanin, V   +5 more
core   +1 more source